Last updated: September 8, 2026
Radium-223 dichloride, marketed by Bayer as Xofigo, is an FDA-approved alpha-particle radiopharmaceutical for symptomatic bone-metastatic castration-resistant prostate cancer. Its development is mature rather than early-stage. Commercial growth depends on treatment sequencing, combination studies, radiopharmaceutical capacity, and competition from lutetium-177 PSMA therapies. The global radium-223 market is likely to remain a mid-hundreds-of-millions-dollar market, with limited upside unless combination or earlier-line use expands the label.
What is the current development status of radium-223?
Xofigo is approved in the United States, European Union and multiple other markets. The active ingredient is radium Ra-223 dichloride, a calcium-mimetic alpha emitter that targets areas of increased bone turnover.
| Development milestone |
Date |
Significance |
| ALSYMPCA Phase 3 results |
2011 |
Demonstrated overall-survival benefit and delayed symptomatic skeletal events |
| FDA approval |
May 15, 2013 |
Approved for symptomatic bone-metastatic CRPC without known visceral metastatic disease |
| European Commission approval |
2013 |
Established EU commercial access |
| Bayer acquisition of Algeta |
2014 |
Bayer obtained full control of Xofigo commercialization and development |
| U.S. label restriction after ERA-223 |
2018 |
Combination with abiraterone acetate and prednisone was contraindicated |
| Current development position |
2025-2026 |
Commercial product with focused combination and sequencing research |
The pivotal ALSYMPCA trial enrolled patients with symptomatic bone-metastatic CRPC who had received or were unsuitable for docetaxel. Radium-223 improved median overall survival to approximately 14.9 months versus 11.3 months for placebo and delayed the first symptomatic skeletal event (Parker et al., 2013).
The approved regimen is six intravenous injections administered at four-week intervals. The recommended dose is 55 kBq/kg per injection.
What is radium-223 approved to treat?
The FDA indication covers patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. Xofigo is not approved for patients with lung, liver or other visceral metastases.
The product is administered by nuclear medicine and radiation-oncology centers. Its use requires radiopharmaceutical handling, patient-specific dosing, radiation-safety controls and post-administration monitoring.
The label does not support routine use with chemotherapy. Xofigo is contraindicated with abiraterone acetate plus prednisone or prednisolone because the ERA-223 trial showed higher fracture and mortality rates in the combination arm (U.S. Food and Drug Administration, 2018).
What did the ERA-223 trial show?
ERA-223 evaluated radium-223 with abiraterone acetate and prednisone in patients with asymptomatic or mildly symptomatic bone-metastatic CRPC. The combination failed to improve symptomatic skeletal-event-free survival and produced more fractures and deaths than placebo with abiraterone and prednisone.
This result materially narrowed the commercial development path. Radium-223 is now positioned primarily as a sequential therapy rather than a broadly combined backbone for metastatic prostate cancer.
What new radium-223 clinical development is underway?
The main development questions concern combination safety, earlier treatment sequencing and integration with androgen-receptor pathway inhibitors or other radiopharmaceuticals.
Radium-223 and enzalutamide
The PEACE-3 trial evaluated radium-223 with enzalutamide in metastatic CRPC. The trial incorporated mandatory bone-protective agents after interim safety findings. This work is relevant because enzalutamide is widely used in advanced prostate cancer, but the commercial opportunity depends on whether the combination improves survival or clinically meaningful disease control without reproducing the fracture signal observed with abiraterone.
Radium-223 and immunotherapy
Studies have evaluated radium-223 with immune checkpoint inhibitors, including pembrolizumab and durvalumab. These programs are biologically rational because alpha radiation may increase tumor-antigen release and local immune activation. Clinical validation has been limited, and no broad immunotherapy combination approval has displaced the established monotherapy indication.
Earlier-line and oligometastatic use
Research has considered radium-223 in patients with less heavily pretreated bone-predominant disease. Earlier use could expand the eligible population, but regulatory success would require a positive survival or skeletal-event endpoint and a clear safety profile in the presence of modern androgen-receptor agents.
Combination with other radiopharmaceuticals
Sequential or combined use with lutetium-177 PSMA therapies is scientifically attractive but operationally difficult. Cumulative marrow toxicity, dosimetry, treatment-center capacity and reimbursement rules constrain this approach. No general FDA-approved radium-223 plus lutetium-177 PSMA regimen exists.
What patents protect Xofigo and radium-223?
The radium-223 patent estate was developed primarily by Algeta and later controlled commercially by Bayer. It covers the active radiopharmaceutical, therapeutic use, formulation and production or handling technology.
Public patent records associate key U.S. filings with Algeta, including:
| Patent area |
Representative U.S. patent |
Commercial relevance |
| Radium-223 therapeutic use |
U.S. Patent No. 8,173,107 |
Protection for use of radium-223 in cancer treatment |
| Radium-223 pharmaceutical composition and use |
U.S. Patent No. 8,617,553 |
Potential protection for product and administration claims |
| Manufacturing and radionuclide production |
Related Algeta patent families |
Creates technical barriers for radioactive active-ingredient supply |
Patent terms depend on priority dates, patent-term adjustment, terminal disclaimers and jurisdiction-specific extensions. The earliest core U.S. claims began reaching the end of their ordinary term in the mid-to-late 2020s. Later formulation, manufacturing and method-of-use patents may extend practical barriers beyond the earliest composition claims.
The estate is stronger against an exact copy of the finished radiopharmaceutical than against all potential competing alpha emitters. Competitors can avoid individual claims by using different radionuclides, chelators, manufacturing routes or treatment protocols.
What is the Orange Book status of Xofigo?
Xofigo is an FDA-approved small-molecule radiopharmaceutical listed under NDA 203971. Its regulatory protection includes approved labeling, FDA exclusivity periods and listed patents.
FDA exclusivity
The principal regulatory exclusivity periods associated with the 2013 approval have expired or are no longer the primary barrier to entry:
- New chemical entity exclusivity: expired.
- Orphan-drug exclusivity: the seven-year period from the 2013 approval expired in 2020.
- Pediatric exclusivity: no material current barrier is generally associated with Xofigo.
The remaining protection is primarily patent-based, together with manufacturing complexity and the limited number of facilities capable of producing, transporting and administering the product.
Paragraph IV challenges
Publicly visible competitive risk is lower than for conventional oral drugs because a generic applicant must reproduce a radioactive injectable product, demonstrate pharmaceutical equivalence and satisfy specialized chemistry, manufacturing and controls requirements.
A Paragraph IV filing against an Orange Book-listed Xofigo patent would be possible under the Hatch-Waxman framework. The practical launch risk would depend on the challenged patent, the applicant's ability to establish a reliable radium-223 supply chain and the outcome of any patent litigation. There has been no widely reported generic launch that has materially displaced Xofigo in the United States.
How strong is the radium-223 patent estate?
The patent estate has moderate commercial strength.
Strengths
- The product has a defined active isotope and pharmaceutical form.
- Radium-223 production requires specialized radioactive-material infrastructure.
- Clinical use claims are supported by a survival-positive Phase 3 trial.
- The treatment is administered through a restricted network of qualified centers.
- Manufacturing, transport and radiation-safety requirements create barriers beyond patent rights.
Weaknesses
- Early core patents approach or reach the end of their ordinary terms.
- The treatment is limited to a narrow patient population.
- The ERA-223 outcome restricts combination use.
- Competing radiopharmaceuticals can target the same disease with different isotopes and mechanisms.
- Method-of-use claims may be vulnerable to label carve-outs or alternative sequencing.
The estate is therefore more defensible as a combined patent, regulatory and manufacturing position than as a stand-alone long-life composition estate.
Which companies are challenging radium-223 commercially?
The principal competitive threat comes from alternative prostate-cancer radiopharmaceuticals rather than an immediate generic copy.
| Product or class |
Company |
Isotope |
Competitive effect |
| Xofigo |
Bayer |
Radium-223 |
Bone-targeted alpha therapy |
| Pluvicto |
Novartis |
Lutetium-177 |
PSMA-targeted beta therapy with broader systemic targeting |
| Lu-177 PSMA programs |
Multiple companies |
Lutetium-177 |
Compete for radiopharmaceutical capacity and treatment slots |
| Actinium-225 PSMA programs |
Multiple biotechnology companies |
Actinium-225 |
Emerging alpha-emitter competition |
| Cabazitaxel and androgen-receptor inhibitors |
Sanofi, Pfizer, Johnson & Johnson and others |
Non-radioactive |
Compete for treatment sequencing and reimbursement |
Pluvicto has a broader target profile because PSMA expression can occur in soft-tissue and visceral disease as well as bone metastases. Xofigo retains a differentiated role in bone-predominant disease, particularly where marrow reserve and treatment-line selection favor a bone-seeking alpha emitter.
How does radium-223 compare with Pluvicto?
| Factor |
Radium-223 |
Lutetium-177 PSMA |
| Target |
Areas of increased bone turnover |
PSMA-expressing tumor cells |
| Radiation |
Alpha particles |
Beta particles with gamma emissions |
| Visceral metastases |
Not approved |
Relevant to approved indications, subject to label |
| Administration |
Six injections every four weeks |
Typically six cycles at longer intervals, depending on label |
| Main toxicity concern |
Bone marrow suppression, fractures in unsafe combinations |
Myelosuppression, salivary-gland effects, renal and other toxicities |
| Commercial positioning |
Bone-predominant CRPC |
PSMA-positive advanced prostate cancer |
| Manufacturing constraint |
Radium-223 supply and radioactive handling |
Lutetium supply, ligand manufacturing and imaging infrastructure |
Pluvicto's commercial expansion increases pressure on Xofigo because both products compete for oncologist referrals, nuclear-medicine capacity and late-line prostate-cancer budgets. Xofigo's differentiated mechanism limits direct substitution but does not eliminate sequencing competition.
What is the market projection for radium-223?
Xofigo revenue has stabilized as a mature specialty product rather than a high-growth oncology asset. Bayer reports product sales in its pharmaceutical segment, while third-party market studies use different geographic and product definitions. Public projections generally place the global radium-223 market in the mid-hundreds-of-millions of dollars annually, with forecasts ranging from approximately $0.8 billion to more than $1.2 billion by the early 2030s depending on assumptions about radiopharmaceutical adoption and label expansion (Grand View Research, 2024; MarketsandMarkets, 2024).
A reasonable base-case projection is:
| Scenario |
2025 global market |
2030 global market |
Key assumption |
| Downside |
$350 million-$500 million |
$300 million-$450 million |
Continued erosion from PSMA therapies and no label expansion |
| Base case |
$500 million-$650 million |
$550 million-$800 million |
Stable bone-metastatic use and modest international growth |
| Upside |
$650 million-$800 million |
$900 million-$1.2 billion |
Positive combination or earlier-line data with broader reimbursement |
These figures represent market estimates, not Bayer guidance. The most probable outcome is low-single-digit growth or market stability. A substantial increase requires evidence that radium-223 improves outcomes when used with a modern androgen-receptor inhibitor or earlier in the treatment pathway.
What drives radium-223 revenue?
Revenue depends on:
- The number of patients with bone-predominant metastatic CRPC.
- Access to qualified radiopharmaceutical centers.
- Reimbursement for six-dose treatment courses.
- Competition from Pluvicto and future actinium-225 products.
- Fracture-risk management and use of bone-protective agents.
- Radium-223 supply and isotope-production capacity.
- Clinical evidence supporting sequencing with other systemic therapies.
What generic launch risks exist for Xofigo?
A conventional generic launch appears less likely to cause rapid erosion than a standard oral oncology generic. The main reasons are:
- Radium-223 requires specialized isotope production.
- The product must be handled under radioactive-material regulations.
- Manufacturing and distribution are time-sensitive.
- Treatment is administered in qualified centers.
- The patient population is narrow and treatment lines are competitive.
- Patent disputes could delay approval or commercial entry.
The higher-risk scenario is a technically capable radiopharmaceutical company entering after core patents expire, supported by an established isotope supply chain and a differentiated reimbursement strategy. Even in that scenario, erosion would likely develop gradually because facility access and prescribing protocols limit immediate substitution.
What licensing deals affect radium-223?
Algeta developed radium-223 and entered a worldwide collaboration with Bayer before Bayer acquired Algeta for approximately $2.9 billion in 2014. The acquisition gave Bayer full control over Xofigo commercialization, manufacturing coordination and future development.
The asset is therefore less exposed to an external royalty burden than a product marketed under a continuing third-party license. The main commercial issue is Bayer's internal allocation of development resources relative to higher-growth radiopharmaceutical assets and competing prostate-cancer products.
What litigation and settlement issues affect radium-223?
No publicly prominent settlement has reshaped the U.S. Xofigo market in the manner seen with major oral oncology products. The principal legal issues are expected to involve:
- Orange Book patent challenges.
- Patent-term calculations.
- Validity of treatment and formulation claims.
- Manufacturing-process claims.
- Regulatory exclusivity and abbreviated-application strategy.
- Label scope for combination or sequencing indications.
The commercial impact of any future litigation would depend on whether a challenger seeks a launch before or after expiration of the principal listed patents and whether it can establish pharmaceutical equivalence for a radioactive injectable product.
Key Takeaways
- Radium-223 is a mature, approved therapy, not an early-stage drug candidate.
- Xofigo remains differentiated for symptomatic bone-metastatic CRPC without known visceral disease.
- The ERA-223 failure materially limits use with abiraterone and prednisone.
- Patent protection is weakening as core U.S. terms approach the mid-to-late 2020s, but manufacturing and regulatory barriers remain important.
- Pluvicto and future actinium-225 therapies are the main commercial threats.
- The base-case global market is approximately $550 million-$800 million by 2030.
- Meaningful upside depends on positive combination or earlier-line clinical data.
- Biosimilar risk is not applicable because radium-223 is a radioactive small-molecule drug, not a biologic.
FAQs
Is radium-223 still commercially relevant after the rise of Pluvicto?
Yes. Xofigo retains a role in bone-predominant symptomatic CRPC, although Pluvicto competes for later-line patients and treatment-center capacity.
Can radium-223 be used with abiraterone?
The combination of Xofigo with abiraterone acetate and prednisone or prednisolone is contraindicated under the U.S. label because of increased fractures and mortality.
Does radium-223 have biosimilar competition?
No. Biosimilar regulation applies to biologic products. Radium-223 is a radioactive small-molecule radiopharmaceutical.
Is Xofigo protected by orphan-drug exclusivity?
The seven-year U.S. orphan-drug exclusivity period associated with the 2013 approval expired in 2020. Patent and manufacturing protections remain more relevant.
What would most increase the radium-223 market?
The strongest commercial catalyst would be a positive Phase 3 result supporting safe use in combination with an androgen-receptor inhibitor or use earlier in metastatic prostate cancer.
References
-
Bayer AG. (2024). Annual report 2023. https://www.bayer.com/en/investors/annual-reports
-
Grand View Research. (2024). Radiopharmaceuticals market size, share and trends analysis report. https://www.grandviewresearch.com/industry-analysis/radiopharmaceuticals-market
-
MarketsandMarkets. (2024). Radiopharmaceuticals market by type, application and end user. https://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-167.html
-
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fossa, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottomley, D., Coleman, R. E., Vogelzang, N. J., O'Bryan-Tear, C. G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, O. S., & Sartor, O. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine, 369(3), 213-223. https://doi.org/10.1056/NEJMoa1213755
-
U.S. Food and Drug Administration. (2018). FDA warns of increased risk of fractures and death with Xofigo when used in combination with Zytiga and prednisone. https://www.fda.gov
-
U.S. Food and Drug Administration. (2025). Drugs@FDA: Xofigo, NDA 203971. https://www.accessdata.fda.gov/scripts/cder/daf/
